Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
Ziylo, a spinout from University of Bristol that is working on a diabetes treatment, has been acquired by Novo Nordisk for a total that could exceed $800m.
Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.
Allied Minds and Bristol-Myers Squibb are joining forces to foster biopharmaceutical research at US universities.
Tsinghua University offers $1.3bn in a takeover bid of smartphone chipset manufacturer Spreadtrum.